Research programme: vascular disease therapeutics - Mannin Research

Drug Profile

Research programme: vascular disease therapeutics - Mannin Research

Alternative Names: MAN 01

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Mannin Research
  • Class Small molecules
  • Mechanism of Action TIE-2 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glaucoma; Polycystic kidney disease

Most Recent Events

  • 31 Dec 2016 Q-BioMed plans to file for international patent applications for MAN 01 (Q-BioMed 10-K, February 2017)
  • 30 Oct 2015 Q-BioMed in-licenses a platform technology from Mannin Research
  • 21 Sep 2015 Preclinical trials in Glaucoma in Canada (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top